Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Malaria Journal
Published in: Malaria Journal 1/2011

Open Access 01-12-2011 | Research

Atorvastatin prevents Plasmodium falciparum cytoadherence and endothelial damage

Authors: Zacharie Taoufiq, Paco Pino, Nadine N'dilimabaka, Issam Arrouss, Serge Assi, Florent Soubrier, Angelita Rebollo, Dominique Mazier

Published in: Malaria Journal | Issue 1/2011

Login to get access

Abstract

Background

The adhesion of Plasmodium falciparum parasitized red blood cell (PRBC) to human endothelial cells (EC) induces inflammatory processes, coagulation cascades, oxidative stress and apoptosis. These pathological processes are suspected to be responsible for the blood-brain-barrier and other organs' endothelial dysfunctions observed in fatal cases of malaria. Atorvastatin, a drug that belongs to the lowering cholesterol molecule family of statins, has been shown to ameliorate endothelial functions and is widely used in patients with cardiovascular disorders.

Methods

The effect of this compound on PRBC induced endothelial impairments was assessed using endothelial co-culture models.

Results

Atorvastatin pre-treatment of EC was found to reduce the expression of adhesion molecules and P. falciparum cytoadherence, to protect cells against PRBC-induced apoptosis and to enhance endothelial monolayer integrity during co-incubation with parasites.

Conclusions

These results might suggest a potential interest use of atorvastatin as a protective treatment to interfere with the pathophysiological cascades leading to severe malaria.
Appendix
Available only for authorised users
Literature
1.
Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI: The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature. 2005, 434: 214-217. 10.1038/nature03342.PubMedCentralCrossRefPubMed
2.
3.
Marsh K, Forster D, Waruiru C, Mwangi I, Winstanley M, Marsh V, Newton C, Winstanley P, Warn P, Peshu N, Pasvol G, Snow R: Indicators of life-threatening malaria in African children. N Engl J Med. 1995, 332: 1399-1404. 10.1056/NEJM199505253322102.CrossRefPubMed
4.
Dondorp A, Nosten F, Stepniewska K, Day N, White N: Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet. 2005, 366: 717-725. 10.1016/S0140-6736(05)67176-0.CrossRefPubMed
5.
Idro R, Jenkins NE, Newton CR: Pathogenesis, clinical features, and neurological outcome of cerebral malaria. Lancet Neurol. 2005, 4: 827-840. 10.1016/S1474-4422(05)70247-7.CrossRefPubMed
6.
van der Heyde HC, Nolan J, Combes V, Gramaglia I, Grau GE: A unified hypothesis for the genesis of cerebral malaria: sequestration, inflammation and hemostasis leading to microcirculatory dysfunction. Trends Parasitol. 2006, 22: 503-508. 10.1016/j.pt.2006.09.002.CrossRefPubMed
7.
Ho M, White NJ: Molecular mechanisms of cytoadherence in malaria. Am J Physiol. 1999, 276: 1231-1242.
8.
Jenkins N, Wu Y, Chakravorty S, Kai O, Marsh K, Craig A: Plasmodium falciparum intercellular adhesion molecule-1-based cytoadherence-related signaling in human endothelial cells. J Infect Dis. 2007, 196: 321-327. 10.1086/518795.PubMedCentralCrossRefPubMed
9.
Pino P, Vouldoukis I, Kolb JP, Mahmoudi N, Desportes-Livage I, Bricaire F, Danis M, Dugas B, Mazier D: Plasmodium falciparum--infected erythrocyte adhesion induces caspase activation and apoptosis in human endothelial cells. J Infect Dis. 2003, 187: 1283-1290. 10.1086/373992.CrossRefPubMed
10.
Tripathi AK, Sha W, Shulaev V, Stins MF, Sullivan DJ: Plasmodium falciparum-infected erythrocytes induce NF-kappaB regulated inflammatory pathways in human cerebral endothelium. Blood. 2009, 114: 4243-4252. 10.1182/blood-2009-06-226415.PubMedCentralCrossRefPubMed
11.
Pino P, Vouldoukis I, Dugas N, Hassani-Loppion G, Dugas B, Mazier D: Redox-dependent apoptosis in human endothelial cells after adhesion of Plasmodium falciparum-infected erythrocytes. Ann N Y Acad Sci. 2003, 1010: 582-586. 10.1196/annals.1299.109.CrossRefPubMed
12.
Taoufiq Z, Gay F, Balvanyos J, Ciceron L, Tefit M, Lechat P, Mazier D: Rho kinase inhibition in severe malaria: thwarting parasite-induced collateral damage to endothelia. J Infect Dis. 2008, 197: 1062-1073. 10.1086/528988.CrossRefPubMed
13.
Tripathi AK, Sullivan DJ, Stins MF: Plasmodium falciparum-infected erythrocytes decrease the integrity of human blood-brain barrier endothelial cell monolayers. J Infect Dis. 2007, 195: 942-950. 10.1086/512083.CrossRefPubMed
14.
Taoufiq Z, Pino P, Dugas N, Conti M, Tefit M, Mazier D, Vouldoukis I: Transient supplementation of superoxide dismutase protects endothelial cells against Plasmodium falciparum-induced oxidative stress. Mol Biochem Parasitol. 2006, 150: 166-173. 10.1016/j.molbiopara.2006.07.008.CrossRefPubMed
15.
Laufs U: Beyond lipid-lowering: effects of statins on endothelial nitric oxide. Eur J Clin Pharmacol. 2003, 58: 719-731.PubMed
16.
Rosenson RS: Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy. Am J Cardiovasc Drugs. 2001, 1: 411-420. 10.2165/00129784-200101060-00001.CrossRefPubMed
17.
Brouet A, Sonveaux P, Dessy C, Moniotte S, Balligand JL, Feron O: Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ Res. 2001, 89: 866-873. 10.1161/hh2201.100319.CrossRefPubMed
18.
Sumi D, Hayashi T, Thakur NK, Jayachandran M, Asai Y, Kano H, Matsui H, Iguchi A: A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects--the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. Atherosclerosis. 2001, 155: 347-357. 10.1016/S0021-9150(00)00597-9.CrossRefPubMed
19.
Romano M, Diomede L, Sironi M, Massimiliano L, Sottocorno M, Polentarutti N, Guglielmotti A, Albani D, Bruno A, Fruscella P, Salmona M, Vecchi A, Pinza M, Mantovani M: Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest. 2000, 80: 1095-1100. 10.1038/labinvest.3780115.CrossRefPubMed
20.
Urbich C, Dernbach E, Zeiher AM, Dimmeler S: Double-edged role of statins in angiogenesis signaling. Circ Res. 2002, 90: 737-744. 10.1161/01.RES.0000014081.30867.F8.CrossRefPubMed
21.
Siau A, Toure FS, Ouwe-Missi-Oukem-Boyer O, Ciceron L, Mahmoudi N, Vaquero C, Froissard P, Bisvigou U, Bisser S, Coppee JY, Bischoff E, David PH, Mazier D: Whole-transcriptome analysis of Plasmodium falciparum field isolates: identification of new pathogenicity factors. J Infect Dis. 2007, 196: 1603-1612. 10.1086/522012.CrossRefPubMed
22.
Zang-Edou ES, Bisvigou U, Taoufiq Z, Lekoulou F, Lekana-Douki JB, Traore Y, Mazier D, Toure-Ndouo FS: Inhibition of Plasmodium falciparum field isolates-mediated endothelial cell apoptosis by Fasudil: therapeutic implications for severe malaria. PLoS One. 2010, 5: e13221-10.1371/journal.pone.0013221.PubMedCentralCrossRefPubMed
23.
Mishra SK, Mohanty S, Mohanty A, Das BS: Management of severe and complicated malaria. J Postgrad Med. 2006, 52: 281-287.PubMed
24.
Muanza K, Gay F, Behr C, Scherf A: Primary culture of human lung microvessel endothelial cells: a useful in vitro model for studying Plasmodium falciparum-infected erythrocyte cytoadherence. Res Immunol. 1996, 147: 149-163. 10.1016/0923-2494(96)83167-1.CrossRefPubMed
25.
26.
Goodyer ID, Johnson J, Eisenthal R, Hayes DJ: Purification of mature-stage Plasmodium falciparum by gelatine flotation. Ann Trop Med Parasitol. 1994, 88: 209-211.PubMed
27.
Brun M, Bourdoulous S, Couraud PO, Elion J, Krishnamoorthy R, Lapoumeroulie C: Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression in cultured human endothelial cells. Pharmacogenomics J. 2003, 3: 215-226. 10.1038/sj.tpj.6500176.CrossRefPubMed
28.
Tripathi AK, Sullivan DJ, Stins MF: Plasmodium falciparum-infected erythrocytes increase intercellular adhesion molecule 1 expression on brain endothelium through NF-kappaB. Infect Immun. 2006, 74: 3262-3270. 10.1128/IAI.01625-05.PubMedCentralCrossRefPubMed
29.
Mason JC: Statins and their role in vascular protection. Clin Sci (Lond). 2003, 105: 251-266. 10.1042/CS20030148.CrossRef
30.
Wolfrum S, Jensen KS, Liao JK: Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol. 2003, 23: 729-736. 10.1161/01.ATV.0000063385.12476.A7.CrossRefPubMed
31.
Schofield L, Novakovic S, Gerold P, Schwarz RT, McConville MJ, Tachado SD: Glycosylphosphatidylinositol toxin of Plasmodium up-regulates intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and E-selectin expression in vascular endothelial cells and increases leukocyte and parasite cytoadherence via tyrosine kinase-dependent signal transduction. J Immunol. 1996, 156: 1886-1896.PubMed
32.
Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997, 91: 231-241. 10.1016/S0092-8674(00)80405-5.CrossRefPubMed
33.
Endres M, Laufs U, Liao JK, Moskowitz MA: Targeting eNOS for stroke protection. Trends Neurosci. 2004, 27: 283-289. 10.1016/j.tins.2004.03.009.CrossRefPubMed
34.
Sobolewski P, Gramaglia I, Frangos J, Intaglietta M, van der Heyde HC: Nitric oxide bioavailability in malaria. Trends Parasitol. 2005, 21 (9): 415-422. 10.1016/j.pt.2005.07.002.CrossRefPubMed
35.
Couto AS, Kimura EA, Peres VJ, Uhrig ML, Katzin AM: Active isoprenoid pathway in the intra-erythrocytic stages of Plasmodium falciparum: presence of dolichols of 11 and 12 isoprene units. Biochem J. 1999, 341: 629-637. 10.1042/0264-6021:3410629.PubMedCentralPubMed
36.
Pradines B, Torrentino-Madamet M, Fontaine A, Henry M, Baret E, Mosnier J, Briolant S, Fusai T, Rogier C: Atorvastatin is 10-fold more active in vitro than other statins against Plasmodium falciparum. Antimicrob Agents Chemother. 2007, 51: 2654-2655. 10.1128/AAC.01330-06.PubMedCentralCrossRefPubMed
37.
Parquet V, Briolant S, Torrentino-Madamet M, Henry M, Almeras L, Amalvict R, Baret E, Fusai T, Rogier C, Pradines B: Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria. Antimicrob Agents Chemother. 2009, 53: 2248-2252. 10.1128/AAC.01462-08.PubMedCentralCrossRefPubMed
38.
Helmers AJ, Gowda DC, Kain KC, Liles WC: Statins fail to improve outcome in experimental cerebral malaria and potentiate Toll-like receptor-mediated cytokine production by murine macrophages. Am J Trop Med Hyg. 2009, 81: 631-637. 10.4269/ajtmh.2009.09-0204.CrossRefPubMed
39.
Kobbe R, Schreiber N, May J, Jacobs T: Simvastatin treatment shows no effect on the incidence of cerebral malaria or parasitemia during experimental malaria. Antimicrob Agents Chemother. 2008, 52: 1583-1584. 10.1128/AAC.01428-07.PubMedCentralCrossRefPubMed
40.
Bienvenu AL, Picot S: Statins alone are ineffective in cerebral malaria but potentiate artesunate. Antimicrob Agents Chemother. 2008, 52: 4203-4204. 10.1128/AAC.00513-08.PubMedCentralCrossRefPubMed
41.
Parquet V, Henry M, Wurtz N, Dormoi J, Briolant S, Gil M, Baret E, Amalvict R, Rogier C, Pradines B: Atorvastatin as a potential anti-malarial drug: in vitro synergy in combinational therapy with quinine against Plasmodium falciparum. Malar J. 2010, 9: 139-10.1186/1475-2875-9-139.PubMedCentralCrossRefPubMed
42.
Savini H, Souraud JB, Briolant S, Baret E, Amalvict R, Rogier C, Pradines B: Atorvastatin as a potential antimalarial drug: in vitro synergy in combinational therapy with dihydroartemisinin. Antimicrob Agents Chemother. 2010, 54: 966-967. 10.1128/AAC.01006-09.PubMedCentralCrossRefPubMed
43.
Wurtz N, Briolant S, Gil M, Parquet V, Henry M, Baret E, Amalvict R, Almeras L, Rogier C, Pradines B: Synergy of mefloquine activity with atorvastatin, but not chloroquine and monodesethylamodiaquine, and association with the pfmdr1 gene. J Antimicrob Chemother. 2010, 65: 1387-1394. 10.1093/jac/dkq173.CrossRefPubMed
44.
Lackner P, Beer R, Helbok R, Broessner G, Engelhardt K, Brenneis C, Schmutzhard E, Pfaller K: Scanning electron microscopy of the neuropathology of murine cerebral malaria. Malar J. 2006, 5: 116-10.1186/1475-2875-5-116.PubMedCentralCrossRefPubMed
45.
White NJ, Turner GD, Medana IM, Dondorp AM, Day NP: The murine cerebral malaria phenomenon. Trends Parasitol. 2009, 26: 11-15. 10.1016/j.pt.2009.10.007.CrossRefPubMed
46.
Zhou Q, Liao JK: Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr Pharm Des. 2009, 15: 467-478. 10.2174/138161209787315684.PubMedCentralCrossRefPubMed
47.
MRC/BHF: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002, 360: 7-22. 10.1016/S0140-6736(02)09327-3.CrossRef
48.
O'Driscoll G, Green D, Taylor RR: Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997, 95: 1126-1131.CrossRefPubMed
49.
Goldstein JL, Brown MS: Regulation of the mevalonate pathway. Nature. 1990, 343: 425-430. 10.1038/343425a0.CrossRefPubMed
50.
Van Aelst L, D'Souza-Schorey C: Rho GTPases and signaling networks. Genes Dev. 1997, 11: 2295-2322. 10.1101/gad.11.18.2295.CrossRefPubMed
51.
Waknine-Grinberg JH, McQuillan JA, Hunt N, Ginsburg H, Golenser J: Modulation of cerebral malaria by fasudil and other immune-modifying compounds. Exp Parasitol. 2010, 125: 141-146. 10.1016/j.exppara.2010.01.005.CrossRefPubMed
Metadata
Title
Atorvastatin prevents Plasmodium falciparum cytoadherence and endothelial damage
Authors
Zacharie Taoufiq
Paco Pino
Nadine N'dilimabaka
Issam Arrouss
Serge Assi
Florent Soubrier
Angelita Rebollo
Dominique Mazier
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2011
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/1475-2875-10-52

Other articles of this Issue 1/2011

Malaria Journal 1/2011 Go to the issue

Research

The clinical burden of malaria in Nairobi: a historical review and contemporary audit

Research

Patterns of anti-malarial drug treatment among pregnant women in Uganda

Research

Impact of combining intermittent preventive treatment with home management of malaria in children less than 10 years in a rural area of Senegal: a cluster randomized trial

Review

Genetic polymorphisms linked to susceptibility to malaria

Review

Plasmodial sugar transporters as anti-malarial drug targets and comparisons with other protozoa

Research

Epidemiology of imported malaria among children and young adults in Barcelona (1990-2008)
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits